Drug Approval | December 05, 2025
Lupin receives FDA’s tentative approval for Siponimod tablets
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Maria Soler Nunez appointed as Chief Quality Officer
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Subscribe To Our Newsletter & Stay Updated
